Evidence map›Paper›PMID 33880444›Full record

ArticleTherapeutic radiology and oncology2019

Stereotactic Ablative Radiotherapy for Central and Ultra-Central Lung Tumors.

Aadel A Chaudhuri, Kevin Chen, Maximilian Diehn, Billy W Loo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic radiology and oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aadel A ChaudhuriDepartment of Radiation Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Kevin ChenDepartment of Radiation Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Maximilian DiehnDepartment of Radiation Oncology and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Billy W LooDepartment of Radiation Oncology and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Funding

Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular CancerK08CA238711 · NCI · WASHINGTON UNIVERSITY · PI CHAUDHURI, AADEL · 2019 to 2021
$647k
NCI NIH HHS K08 CA238711
6 · The paper itself

Abstract

Stereotactic ablative radiotherapy (SABR) has emerged as a standard-of-care treatment for patients with early stage non-small cell lung cancer (NSCLC) who are poor surgical candidates. Current evidence supports the consensus that lung SABR with BED ≥100 Gy leads to high local tumor control, and that the treatment is generally well-tolerated when applied to peripheral lung tumors. However, several studies present conflicting evidence for the treatment of central and ultra-central lung tumors, with some showing superb outcomes and others showing concerning rates of morbidity and mortality. Therefore, treatment of central and especially ultra-central lung tumors with SABR remains controversial. In this review, we aim to present the existing evidence for SABR treatment of central and ultra-central lung tumors and delineate the factors that could lead to significant toxicity.

Identifiers

PMID33880444
PMCPMC8054989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.